New combo therapy aims to shrink rectal tumors and save sphincters
NCT ID NCT06493240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding a PD-1 inhibitor (Sintilimab) after standard chemoradiotherapy could improve outcomes for 30 patients with locally advanced mid-low rectal cancer. Participants received radiation and chemotherapy, then three doses of Sintilimab, followed by surgery. The study measured how many patients had a complete tumor disappearance and how many could keep their anal sphincter.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (PD-1 inhibitor) combined with capecitabine-based chemoradiotherapy
What this could lead to
If successful, this combination could increase the chance of eliminating the tumor before surgery and help more patients avoid permanent colostomy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Immune-related side effects from the PD-1 inhibitor are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China